NO975434L - Fremgangsmåte for fremstilling av influensa hemagglutinin multivalente vaksiner - Google Patents

Fremgangsmåte for fremstilling av influensa hemagglutinin multivalente vaksiner

Info

Publication number
NO975434L
NO975434L NO975434A NO975434A NO975434L NO 975434 L NO975434 L NO 975434L NO 975434 A NO975434 A NO 975434A NO 975434 A NO975434 A NO 975434A NO 975434 L NO975434 L NO 975434L
Authority
NO
Norway
Prior art keywords
recombinant
influenza
purification
preparation
insect cells
Prior art date
Application number
NO975434A
Other languages
English (en)
Other versions
NO975434D0 (no
Inventor
Gale Eugene Smith
Franklin Volvovitz
Bethanie E Wilkinson
Andrei I Voznesensky
Craig Stanway Hackett
Original Assignee
Mg Pmc Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27508642&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO975434(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA2222129A priority Critical patent/CA2222129C/en
Application filed by Mg Pmc Llc filed Critical Mg Pmc Llc
Priority to NO975434A priority patent/NO975434L/no
Publication of NO975434D0 publication Critical patent/NO975434D0/no
Publication of NO975434L publication Critical patent/NO975434L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/816—Viral vaccine for avian species, e.g. poultry or other birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En fremgangsmåte for fremstilling av rekombinant influensavaksine ved anvendelse av DNA-teknologi ble fremskaffet. Den resulterende vaksinen er en multivalent, fortrinnsvis trivalent, influensavaksine basert på en blanding av det rekombinante hemagglutinin antigenet klonet fra influensavira med epidemisk potensiale. De rekombinante hemagglutinin antigenene er fullengde, uspaltede ((HAO), glykoproteiner produsert av baculovirus-ekspresjonsvektor i dyrkede insektsceller og renset under ikke- denaturerende betingelser. I den foretrukne utførelsesformen blir de klonede HA-genene modifisert ved deletering av naturlige hydrofobe signalpeptidsekvenser og erstatning av dem med et nytt baculovirus kitinasesignalpeptid. En generell tilnærming for effektiv ekstraksjon og rensing av rekombinant HA-protein produsert i insektsceller er også beskrevet for rensing av rHA-proteiner fra A subtyper og B type influensavira.
NO975434A 1993-09-13 1997-11-26 Fremgangsmåte for fremstilling av influensa hemagglutinin multivalente vaksiner NO975434L (no)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA2222129A CA2222129C (en) 1993-09-13 1995-05-26 A method for producing influenza hemagglutinin multivalent vaccines
NO975434A NO975434L (no) 1993-09-13 1997-11-26 Fremgangsmåte for fremstilling av influensa hemagglutinin multivalente vaksiner

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US08/120,607 US5762939A (en) 1993-09-13 1993-09-13 Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
PCT/US1995/006750 WO1996037624A1 (en) 1993-09-13 1995-05-26 A method for producing influenza hemagglutinin multivalent vaccines
CA2222129A CA2222129C (en) 1993-09-13 1995-05-26 A method for producing influenza hemagglutinin multivalent vaccines
CNB951979280A CN100390289C (zh) 1993-09-13 1995-05-26 生产流感血凝素多价疫苗的方法
NO975434A NO975434L (no) 1993-09-13 1997-11-26 Fremgangsmåte for fremstilling av influensa hemagglutinin multivalente vaksiner
LT97-201A LT4461B (lt) 1993-09-13 1997-12-23 Gripo hemagliutinino multivalentinių vakcinų gamybos būdas

Publications (2)

Publication Number Publication Date
NO975434D0 NO975434D0 (no) 1997-11-26
NO975434L true NO975434L (no) 1998-01-19

Family

ID=27508642

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975434A NO975434L (no) 1993-09-13 1997-11-26 Fremgangsmåte for fremstilling av influensa hemagglutinin multivalente vaksiner

Country Status (22)

Country Link
US (2) US5762939A (no)
EP (2) EP1605052B1 (no)
JP (1) JP3757318B2 (no)
CN (1) CN100390289C (no)
AT (2) ATE518000T1 (no)
AU (1) AU712776B2 (no)
BR (1) BR9510590A (no)
CA (1) CA2222129C (no)
CZ (2) CZ301021B6 (no)
DE (1) DE69534449T2 (no)
DK (3) DK0833933T3 (no)
ES (1) ES2248799T3 (no)
FI (1) FI974319A (no)
HK (1) HK1083867A1 (no)
HU (1) HUT77921A (no)
IS (1) IS4620A (no)
LT (1) LT4461B (no)
NO (1) NO975434L (no)
NZ (1) NZ288026A (no)
PT (1) PT1605052E (no)
SK (1) SK286441B6 (no)
WO (1) WO1996037624A1 (no)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387373B1 (en) * 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
EP2374894B1 (en) * 1993-09-13 2014-09-17 Protein Sciences Corporation A method for producing influenza hemagglutinin multivalent vaccines
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) * 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
US7157089B1 (en) * 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
DK1002110T3 (da) * 1997-08-05 2003-05-26 Stressgen Biotechnologies Corp Immunsvar mod HPV-antigener fremkaldt af sammensætninger, som omfatter et HPV-antigen og et stressprotein eller en ekspressionsvektor i stand til at ekspressere disse proteiner
US20030045492A1 (en) * 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6348450B1 (en) * 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US20030125278A1 (en) * 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US8026096B1 (en) * 1998-10-08 2011-09-27 Protein Sciences Corporation In vivo active erythropoietin produced in insect cells
MXPA01006214A (es) * 1998-12-17 2004-09-06 Aventis Pasteur Composicion inmunogenica multivalente que contiene una preparacion de virus de influenza y una composicion de subunidad del virus sincicial respiratorio.
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
AU5926700A (en) 1999-07-08 2001-01-30 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
US6544750B1 (en) 1999-08-17 2003-04-08 Thromgen, Inc. Peptide analogs as selective inhibitors of thrombin activation of protease activated receptor 1
DE19963857A1 (de) * 1999-12-30 2001-07-26 Qiagen Gmbh Primer, insbesondere für Primer-abhängige Nukleinsäure-Syntheseprozesse und Nukleinsäure-Amplifikationsverfahren
KR100919266B1 (ko) * 2000-06-26 2009-09-30 엔벤타 바이오파마슈티컬스 코포레이션 인간 파필로마 바이러스 치료법
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
GB0022969D0 (en) * 2000-09-19 2000-11-01 Chiron Spa Influenza a virus subtype H16
US20040071733A1 (en) * 2001-02-05 2004-04-15 Hiroshi Takaku Baculovirus vector vaccine
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
US7232670B2 (en) * 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
DE10218129A1 (de) * 2002-04-23 2003-11-20 Univ Ruprecht Karls Heidelberg Genetischer Impfstoff gegen RNA-Virus-Infektionen
WO2005018539A2 (en) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
AU2004249802B2 (en) * 2003-06-20 2007-06-28 Microbix Biosystems Inc. Improvements in virus production
EP1668112A4 (en) 2003-06-20 2009-04-29 Protein Sciences Corp SARS IMMUNOGENOUS EXPRESSING VECTORS, SUCH VECTORS OR EXPRESSION PRODUCTS COMPRISING THOSE COMPOSITIONS, PROCESSES AND TESTS FOR THE PREPARATION AND USE THEREOF
US8992939B2 (en) 2003-07-11 2015-03-31 Novavax, Inc. Highly efficient influenza matrix (M1) proteins
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US8506967B2 (en) 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
US7527967B2 (en) * 2003-11-25 2009-05-05 Academia Sinica Recombinant baculovirus and virus-like particle
AU2005319099B2 (en) 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
GB2429207A (en) 2004-02-02 2007-02-21 Ambrx Inc Modified human interferon polypeptides and their uses
US7342107B2 (en) 2004-05-27 2008-03-11 Centocor, Inc. Cynomolgus prostate specific antigen
US20050276758A1 (en) * 2004-06-15 2005-12-15 Marshall Deborah J Method for screening agents against human prostate disease
KR101699142B1 (ko) * 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
EP1771573A4 (en) * 2004-07-21 2009-02-18 Ambrx Inc BIOSYNTHETIC POLYPEPTIDES OBTAINED FROM NON-NATURALLY CITED AMINO ACIDS
EP1836298B1 (en) * 2004-12-22 2012-01-18 Ambrx, Inc. COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
US7816320B2 (en) * 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
DK1828224T3 (en) 2004-12-22 2016-07-18 Ambrx Inc Compositions containing, methods including, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES
EP1841785A2 (en) 2005-01-19 2007-10-10 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
WO2006091722A2 (en) * 2005-02-23 2006-08-31 Uab Research Foundation Alkyl-glycoside enhanced vaccination
EP2441471B1 (en) 2005-03-08 2014-10-08 MedImmune, LLC Reassortant influenza viruses
JP5869744B2 (ja) 2005-03-23 2016-02-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｃｄ４ｔ細胞および／または改善された記憶ｂ細胞応答を誘導するためのインフルエンザウイルスおよび水中油型エマルジョンアジュバントの使用
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
ATE529442T1 (de) * 2005-06-03 2011-11-15 Ambrx Inc Verbesserte humane interferon-moleküle und ihre verwendungen
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
AU2005335491B2 (en) 2005-08-18 2010-11-25 Ambrx, Inc. Compositions of tRNA and uses thereof
EP1926780B1 (en) 2005-09-22 2013-08-14 Medivas, LLC Bis-( -amino)-diol-diester-containing poly(ester amide) and poly(ester urethane) compositions and methods of use
WO2007038246A2 (en) * 2005-09-22 2007-04-05 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
US7468187B2 (en) 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
US20110180430A1 (en) 2005-11-04 2011-07-28 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines including cytokine-inducing agents
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
WO2007052155A2 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
CA2628152C (en) * 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
DE602006020480D1 (de) * 2005-11-08 2011-04-14 Ambrx Inc Beschleuniger für die modifikation nichtnatürlicher aminosäuren und nichtnatürlicher aminosäurepolypeptide
PT2339014E (pt) * 2005-11-16 2015-10-13 Ambrx Inc Métodos e composições compreendendo aminoácidos não-naturais
WO2007067744A2 (en) * 2005-12-07 2007-06-14 Medivas, Llc Method for assembling a polymer-biologic delivery composition
EP1968635B1 (en) * 2005-12-14 2014-09-17 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
DK1976559T6 (da) 2006-01-27 2020-04-06 Seqirus Uk Ltd Influenzavacciner indeholdende hæmagglutinin og matrixproteiner
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
US9333249B2 (en) 2006-02-09 2016-05-10 Educational Foundation Jichi Medical University Recombinant baculovirus vaccine
CU23576A1 (es) 2006-02-28 2010-09-30 Ct Ingenieria Genetica Biotech Antígenos vacunales quiméricos contra el virus de la influenza aviar
EP2476432B1 (en) * 2006-03-07 2015-08-19 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
EP2004226A1 (en) 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Storage of influenza vaccines without refrigeration
CA2649672C (en) * 2006-05-02 2015-07-07 Medivas, Llc Delivery of ophthalmologic agents to the exterior or interior of the eye
CN102258778B (zh) * 2006-05-05 2014-08-13 淡马锡生命科学研究院有限公司 生物分子表面展示及其用途
US20070282011A1 (en) * 2006-05-09 2007-12-06 Medivas, Llc Biodegradable water soluble polymers
KR101696727B1 (ko) 2006-07-17 2017-01-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 인플루엔자 백신
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
DK2615108T3 (en) * 2006-09-08 2017-01-30 Ambrx Inc Modified human plasma polypeptide or fc scaffolds and their applications
WO2008030614A2 (en) * 2006-09-08 2008-03-13 Ambrx, Inc. Suppressor trna transcription in vertebrate cells
WO2008030613A2 (en) * 2006-09-08 2008-03-13 Ambrx, Inc. Hybrid suppressor trna for vertebrate cells
US20100105025A1 (en) * 2006-10-12 2010-04-29 Engelhard Eric K Devices for generating detectable polymers
US20080124710A1 (en) * 2006-10-12 2008-05-29 Engelhard Eric K Devices for generating detectable polymers
WO2008118487A2 (en) * 2007-03-26 2008-10-02 University Of Massachusetts Medical School Compositions and methods for incresing immunogenicity of glycoprotein vaccines
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
CN103965347B (zh) 2007-05-02 2017-07-18 Ambrx公司 经修饰干扰素β多肽和其用途
EA201070066A1 (ru) * 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
CA2615372A1 (en) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
EP2178944A1 (en) * 2007-07-24 2010-04-28 Medivas, LLC Biodegradable cationic polymer gene transfer compositions and methods of use
AU2008326324B9 (en) 2007-11-20 2012-11-15 Ambrx, Inc. Modified insulin polypeptides and their uses
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
CN103122354B (zh) 2007-11-27 2018-03-23 麦迪卡格公司 表达血凝素之转基因植物中生产的重组流感病毒样颗粒(vlp)
EP3103880A1 (en) 2008-02-08 2016-12-14 Ambrx, Inc. Modified leptin polypeptides and their uses
ES2594102T3 (es) * 2008-04-18 2016-12-15 Vaxinnate Corporation Mutantes por deleción de la flagelina y métodos para su uso
WO2010003235A1 (en) * 2008-07-08 2010-01-14 Medicago Inc. Soluble recombinant influenza antigens
SG192501A1 (en) 2008-07-11 2013-08-30 Medimmune Llc Influenza hemagglutinin and neuraminidase variants
UA118536C2 (uk) * 2008-07-23 2019-02-11 Амбркс, Інк. Модифікований поліпептид бичачого гранулоцитарного колонієстимулювального фактора та його застосування
JP2012500207A (ja) * 2008-08-13 2012-01-05 メディバス エルエルシー Ａａｂｂ−ポリ（デプシペプチド）生分解性ポリマー及び使用方法
US8658180B2 (en) 2008-08-15 2014-02-25 Mark A. Miller Vaccines against influenza virus
MX348657B (es) 2008-09-26 2017-06-21 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
EP3216800A1 (en) * 2008-09-26 2017-09-13 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
DK2396032T3 (en) 2009-02-10 2016-12-19 Seqirus Uk Ltd Influenza vaccines with reduced amounts of squalene
DE102010018462A1 (de) 2009-04-27 2011-04-07 Novartis Ag Impfstoffe zum Schutz gegen Influenza
CA2763440A1 (en) 2009-05-29 2010-12-02 Novartis Ag Assays for influenza virus hemagglutinins
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
GB2471093A (en) * 2009-06-17 2010-12-22 Cilian Ag Viral protein expression in ciliates
NZ597401A (en) 2009-06-24 2013-09-27 Medicago Inc Chimeric influenza virus-like particles comprising hemagglutinin
CN102482666B (zh) 2009-07-06 2017-02-08 变异生物技术公司 制备囊泡的方法和由其产生的制剂
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US8810417B2 (en) * 2009-08-28 2014-08-19 The Invention Science Fund I, Llc Beverage immersate with detection capability
US9024766B2 (en) * 2009-08-28 2015-05-05 The Invention Science Fund, Llc Beverage containers with detection capability
CN102695523A (zh) 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
KR20180026562A (ko) 2009-09-22 2018-03-12 메디카고 인코포레이티드 식물-유래 단백질의 제조방법
NZ600363A (en) 2009-12-21 2014-07-25 Ambrx Inc Modified porcine somatotropin polypeptides and their uses
CN102753573A (zh) 2009-12-21 2012-10-24 Ambrx公司 经过修饰的牛促生长素多肽和其用途
AU2010343095B2 (en) * 2009-12-28 2017-01-05 Sanofi Vaccine Technologies, S.A.S. Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof
EP2519636B8 (en) * 2009-12-28 2017-08-09 DSM IP Assets B.V. Production of hemagglutinin-neuraminidase protein in microalgae
CN102939101A (zh) * 2010-01-26 2013-02-20 科罗拉多大学董事会，法人 用于通用疫苗的流感病毒组合物和方法
JP2013522231A (ja) * 2010-03-11 2013-06-13 イミューン デザイン コーポレイション インフルエンザのためのワクチン
EP3187585A1 (en) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
PL2575872T3 (pl) 2010-06-01 2021-02-22 Seqirus UK Limited Zatężanie antygenów szczepionkowych grypy bez liofilizacji
JP5976639B2 (ja) 2010-06-01 2016-08-23 ノバルティス アーゲー インフルエンザワクチン抗原の濃縮および凍結乾燥
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
BR112013003522B1 (pt) 2010-08-17 2021-05-25 Ambrx, Inc. polipeptídeos relaxina modificados compreendendo um aminoácido não codificado naturalmente, seu método de preparação e seu uso, bem como ácido nucleico e célula hospedeira
AU2011290471B2 (en) 2010-08-20 2015-08-20 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
US8513006B2 (en) 2010-09-14 2013-08-20 University of Pittsburgh—of the Commonwealth System of Higher Education Tetravalent influenza vaccine and use thereof
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
CN102023213B (zh) * 2010-09-28 2014-04-02 汕头大学医学院 一种检测流感病毒抗体的荧光微量细胞凝集方法
AU2012205315B2 (en) 2011-01-13 2017-05-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CN103501811B (zh) 2011-01-13 2016-03-30 变异生物技术公司 用于治疗病毒感染的组合物和方法
EP3205353B1 (en) 2011-03-21 2021-01-13 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
EP3159368A1 (en) 2011-06-23 2017-04-26 DSM IP Assets B.V. New biodegradable polyesteramide copolymers for drug delivery
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
WO2013057715A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
WO2013072768A2 (en) 2011-11-18 2013-05-23 Variation Biotechnologies, Inc. Synthetic derivatives of mpl and uses thereof
EP2791680B1 (en) 2011-12-12 2015-12-09 Novartis AG Assay for influenza virus hemagglutinins
CA2894442C (en) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
RU2698906C2 (ru) 2012-01-27 2019-09-02 Вэриэйшн Биотекнолоджиз, Инк. Способы и композиции для терапевтических агентов
TWI434933B (zh) * 2012-04-17 2014-04-21 Nat Univ Tsing Hua 抗多型禽流感病毒之ｄｎａ疫苗及其組合物
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
JP2015015931A (ja) 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ウイルス様粒子を含む培養物の製造方法
JP6479305B2 (ja) 2013-07-12 2019-03-06 株式会社Ｕｍｎファーマ ウイルス様粒子の精製方法
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
KR20240024362A (ko) 2014-10-24 2024-02-23 브리스톨-마이어스 스큅 컴퍼니 변형된 fgf-21 폴리펩티드 및 그의 용도
CN107106509B (zh) 2014-12-18 2021-11-30 帝斯曼知识产权资产管理有限公司 用于递送酸敏感药物的药物递送系统
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
WO2016179099A1 (en) * 2015-05-04 2016-11-10 Epivax, Inc. Modified h7 hemagluttinin glycoprotein of the influenza a/shanghai/2/2013 h7 sequence
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines
HUE051783T2 (hu) * 2015-07-07 2021-03-29 Seqirus Uk Ltd Eljárás immunogén hemagglutinin mennyiségi meghatározására
BR112018014109A2 (pt) 2016-01-11 2018-12-11 Verndari Inc composições de microagulhas e métodos de uso das mesmas
CN106749554B (zh) * 2017-01-20 2021-01-15 中山大学 一种流感病毒血凝素蛋白的纯化方法
CN110637027A (zh) 2017-02-08 2019-12-31 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
US10874737B2 (en) 2018-06-01 2020-12-29 Iowa State University Research Foundation, Inc. Influenza nanovaccine
MX2023002339A (es) 2020-08-24 2023-03-22 Sanofi Pasteur Inc Vacunas contra infecciones por sars-cov-2.
CA3190375A1 (en) 2020-08-24 2022-03-03 Natalie ANOSOVA Covid-19 vaccines with tocopherol-containing squalene emulsion adjuvants
CA3233926A1 (en) 2021-10-08 2023-04-13 Sanofi Pasteur Inc. Multivalent influenza vaccines
CA3237134A1 (en) 2021-11-05 2023-05-11 Timothy ALEFANTIS Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same
AU2022381813A1 (en) 2021-11-05 2024-06-20 Sanofi Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same
US20240042021A1 (en) 2022-08-01 2024-02-08 Flagship Pioneering Innovations Vii, Llc Immunomodulatory proteins and related methods
WO2024077118A2 (en) 2022-10-06 2024-04-11 Bicara Therapeutics Inc. Multispecific proteins and related methods
CN116763915B (zh) * 2023-08-17 2023-11-03 山东兴瑞生物科技有限公司 一种用于治疗和预防流感病毒的多价疫苗

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029763A (en) * 1974-08-05 1977-06-14 Mount Sinai School Of Medicine Of The City University Of New York Influenza vaccine containing purified neuraminidase antigen and method of using the same
IN150740B (no) * 1978-11-24 1982-12-04 Hoffmann La Roche
US4659669A (en) * 1981-03-02 1987-04-21 Regents Of The Univ. Of California Microbial expression of human influenza hemagglutinin proteins
US4752473A (en) * 1984-10-12 1988-06-21 The Regents Of The University Of California Expression of glycosylated human influenza hemagglutinin proteins
US4920213A (en) * 1985-06-20 1990-04-24 Biotechnology Research Partners, Ltd. Method and compositions useful in preventing equine influenza
EP0349594A4 (en) * 1987-03-16 1990-09-26 American Biogenetic Sciences, Inc. Recombinant baculovirus occlusion bodies in vaccines and biological insecticides
GB9106185D0 (en) * 1991-03-22 1991-05-08 Wellcome Found Biological control agents
CA2084180A1 (en) * 1991-12-11 1993-06-12 Paul P. Hung Expression of specific immunogens using viral antigens
AU2517995A (en) * 1994-05-20 1995-12-18 Microgenesys, Inc. Immunogenic carcinoembryonic antigen and methods of use and production

Also Published As

Publication number Publication date
US5762939A (en) 1998-06-09
EP0833933A1 (en) 1998-04-08
DK1275726T3 (da) 2008-06-23
CN100390289C (zh) 2008-05-28
ES2248799T3 (es) 2006-03-16
CN1194005A (zh) 1998-09-23
EP1605052B1 (en) 2011-07-27
CA2222129C (en) 2010-04-27
NZ288026A (en) 1999-11-29
US5858368A (en) 1999-01-12
LT4461B (lt) 1999-02-25
PT1605052E (pt) 2011-10-19
CZ301021B6 (cs) 2009-10-14
DK0833933T3 (da) 2005-10-10
FI974319A0 (fi) 1997-11-25
IS4620A (is) 1997-11-25
DE69534449D1 (de) 2006-01-26
BR9510590A (pt) 1999-11-30
FI974319A (fi) 1998-01-22
DE69534449T2 (de) 2006-07-06
EP1605052A3 (en) 2008-08-13
JP3757318B2 (ja) 2006-03-22
ATE304602T1 (de) 2005-09-15
SK158897A3 (en) 1999-06-11
AU2692595A (en) 1996-12-11
EP0833933B1 (en) 2005-09-14
ATE518000T1 (de) 2011-08-15
HK1083867A1 (en) 2006-07-14
SK286441B6 (sk) 2008-10-07
CA2222129A1 (en) 1996-11-28
CZ373897A3 (cs) 1999-02-17
WO1996037624A1 (en) 1996-11-28
LT97201A (en) 1998-09-25
CZ299862B6 (cs) 2008-12-17
EP1605052A2 (en) 2005-12-14
AU712776B2 (en) 1999-11-18
DK1605052T3 (da) 2011-11-07
HUT77921A (hu) 1998-10-28
JP2000513922A (ja) 2000-10-24
NO975434D0 (no) 1997-11-26

Similar Documents

Publication Publication Date Title
NO975434L (no) Fremgangsmåte for fremstilling av influensa hemagglutinin multivalente vaksiner
DK0791055T3 (da) Fremgangsmåde til fremstilling af biologiske produkter i proteinfri kultur
LU91367I2 (fr) Un vaccin à virus complet de l'influenza inactivéepréparé à partir d'une souche germe produite en u tlilisant la génétique inverse et facultativement comprenant un adjuvant
GEP20084431B (en) Papilloma virus vaccine
ATE119042T1 (de) Verwendung eines viralen glykoprotein-impstoffes für intranasale immunisierung gegen eine virusinfektion.
ATE7855T1 (de) Herstellung von virusantigenen.
ATE238065T1 (de) Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus
DK656687D0 (da) Bakterielle antigener, antistoffer, vacciner og fremgangsmaade til fremstilling deraf
DK0480949T3 (da) Fremstilling af virus og oprensning af virale kappeproteiner til vaccineanvendelse
NO20032097D0 (no) Gj¶ravledet vaksine mot IPNV
KR880000579A (ko) 베리셀라-죠스터 바이러스의 생산방법
DE69535716D1 (de) Methode für die Produktion von multivalenten Influenza Hämagglutinin Vakzinen
EP2374894A3 (en) A method for producing influenza hemagglutinin multivalent vaccines
WO1997027742B1 (en) Method of protein production using mitochondrial translation system
Rott et al. Activation of Influenza Virus Infectivity by Proteolytic Cleavage of the Hemagglutinin
Knight Immunogenic properties of PR8 influenza virus after treatment with acid protease
Tsiang Different behaviour of fixed and street rabies virus strains in cultured rat myotubes
TH35753C3 (th) อิมมูโนเจนที่ถูกเพิ่มกำลัง สำหรับวัคซีนเชื้อตายเพื่อต่อสู้กับโรคที่เป็นการติดเชื้อ ที่มีสาเหตุมาจากกลุ่มของเจเปเนส เอนซีฟาไลทีสไวรัสและวิธีการเพื่อผลิตสิ่งนั้น
Server et al. Comparison of the F1 NH2-terminal region of a fusing and a non-fusing strain of mumps virus
Akopova et al. Genomic and antigenic analysis of influenza A(H 1 N 1) virus strains isolated in 1982-1983: Approaches to selection of an optimal vaccine strain.
RU93026961A (ru) Способ получения инактивированной гриппозной вакцины
TH58373A3 (th) อิมมูโนเจนที่ถูกเพิ่มกำลัง สำหรับวัคซีนเชื้อตายเพื่อต่อสู้กับโรคที่เป็นการติดเชื้อ ที่มีสาเหตุมาจากกลุ่มของเจเปเนส เอนซีฟาไลทีสไวรัสและวิธีการเพื่อผลิตสิ่งนั้น
ATE126702T1 (de) Verfahren zur herstellung von impfstoffen gegen rna-virus.
MX9802766A (es) Vacuna contra la influenza.
FR2596771B1 (fr) Vecteur viral et adn recombinant codant pour une glycoproteine du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la glycoproteine, glycoproteine obtenue, vaccin et anticorps obtenus

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application